Diazoxide Salt Formulations for Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral formulations of diazoxide for treating diabetes and obesity are limited by adverse side effects such as dyspepsia, nausea, and fluid retention, which restrict their utility, especially in obese subjects, and there is a challenge in producing stable salts of diazoxide and its derivatives.
Innovation Solution
Development of alkali metal, tertiary amine, and ammonium salts of diazoxide and its derivatives, specifically formulated as KATP channel openers that inhibit glucose-induced insulin release, with controlled release pharmaceutical formulations to reduce adverse effects and improve bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current oral formulations of diazoxide are used to treat diabetes and obesity, then therapeutic effect is achieved, but adverse side effects such as dyspepsia, nausea, and fluid retention occur
Solution Approach 1:
The patent applies parameter changes by developing controlled-release formulations that modify the release kinetics of diazoxide. This transforms the drug delivery parameter from immediate release to controlled release, thereby maintaining therapeutic efficacy while reducing peak plasma concentrations that cause adverse side effects like dyspepsia, nausea, and fluid retention
Solution Approach 2:
The patent employs preliminary action through the development of stable salt forms of diazoxide (such as diazoxide sulfate and diazoxide hydrochloride) before clinical administration. These pre-stabilized salt forms ensure consistent drug delivery and reduce variability in absorption, which helps minimize adverse effects while maintaining reliable therapeutic outcomes
2Reliability
If stable salts of diazoxide are produced for therapeutic use, then bioavailability is improved, but manufacturing complexity increases
Solution Approach 1:
The patent uses intermediary compounds such as sulfuric acid and hydrochloric acid as mediators to convert diazoxide into stable salt forms. These intermediary reagents facilitate the formation of diazoxide sulfate and diazoxide hydrochloride salts, which exhibit improved bioavailability and stability while maintaining relatively simple manufacturing processes through standard pharmaceutical salt formation techniques
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new formulations provide improved bioavailability and reduced adverse effects, enabling effective treatment of diabetes and obesity with enhanced safety and compliance, while stabilizing diazoxide salts for therapeutic use.
Implementation Method 1
KATP channel openers (PCOs or KCOs; also referred to as channel activators or channel agonists), are a structurally diverse group of compounds with no apparent common pharmacophore linking their ability to antagonize the inhibition of KATP channels by intracellular nucleotides
Data Source
AI summary
Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic an compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.